06:07 AM EDT, 09/17/2025 (MT Newswires) -- Eli Lilly's ( LLY ) international business president said it was too early to assume the company will use the US Food and Drug Administration's new fast-track review process for its experimental weight-loss pill, orforglipron, Reuters reported Wednesday, citing an interview.

"There is very little knowledge about this national priority voucher today. I would not assume we will submit with a national priority voucher, because we do not fully understand what it contains," said Patrik Jonsson, president of Lilly International, according to the report.

Eli Lilly ( LLY ) did not immediately respond to an MT Newswires request for comment on the report.

The company said on Tuesday, however, that a phase 3 study of orforglipron met its primary endpoint, with all three doses of orforglipron demonstrating "superior body weight reduction" compared with placebo.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)